EA200500633A1 - Ингибиторы гидролазы амидов жирных кислот - Google Patents

Ингибиторы гидролазы амидов жирных кислот

Info

Publication number
EA200500633A1
EA200500633A1 EA200500633A EA200500633A EA200500633A1 EA 200500633 A1 EA200500633 A1 EA 200500633A1 EA 200500633 A EA200500633 A EA 200500633A EA 200500633 A EA200500633 A EA 200500633A EA 200500633 A1 EA200500633 A1 EA 200500633A1
Authority
EA
Eurasian Patent Office
Prior art keywords
faah
inhibitors
hydrolase
competitive inhibitors
fatty acids
Prior art date
Application number
EA200500633A
Other languages
English (en)
Other versions
EA008767B1 (ru
Inventor
Дэйл Л. Богер
Original Assignee
Зе Скрипс Ресеч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Скрипс Ресеч Инститьют filed Critical Зе Скрипс Ресеч Инститьют
Publication of EA200500633A1 publication Critical patent/EA200500633A1/ru
Publication of EA008767B1 publication Critical patent/EA008767B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Усовершенствованные конкурентные ингибиторы ГАЖК, в которых используют α-кетогетероциклический фармакофор и связывающую подгруппу, имеющую π-ненасыщенность. α-Кетогетероциклический фармакофор и связывающая подгруппа присоединены к друг другу предпочтительно углеводородной цепью. Усовершенствование заключается в использовании гетероциклического фармакофора, выбранного из оксазолов, оксадиазолов, тиазолов и тиадиазолов, имеющих в 4 и/или 5 положениях алкильные или арильные заместители. Усовершенствованные конкурентные ингибиторы ГАЖК проявляют повышенную активность по сравнению с обычными конкурентными ингибиторами ГАЖК.Отчет о международном поиске был опубликован 2004.09.16.
EA200500633A 2002-10-08 2003-10-08 Ингибиторы гидролазы амидов жирных кислот EA008767B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41724702P 2002-10-08 2002-10-08
PCT/US2003/031975 WO2004033652A2 (en) 2002-10-08 2003-10-08 Inhibitors of fatty acid amide hydrolase

Publications (2)

Publication Number Publication Date
EA200500633A1 true EA200500633A1 (ru) 2005-10-27
EA008767B1 EA008767B1 (ru) 2007-08-31

Family

ID=32093990

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500633A EA008767B1 (ru) 2002-10-08 2003-10-08 Ингибиторы гидролазы амидов жирных кислот

Country Status (15)

Country Link
US (1) US7662971B2 (ru)
EP (2) EP2093220A3 (ru)
JP (1) JP4628789B2 (ru)
KR (1) KR20050070041A (ru)
CN (1) CN1703407A (ru)
AT (1) ATE431342T1 (ru)
AU (1) AU2003275493A1 (ru)
BR (1) BR0314980A (ru)
CA (1) CA2501575A1 (ru)
DE (1) DE60327640D1 (ru)
EA (1) EA008767B1 (ru)
ES (1) ES2325686T3 (ru)
MX (1) MXPA05003762A (ru)
WO (1) WO2004033652A2 (ru)
ZA (1) ZA200501837B (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462054B1 (en) * 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
AU2003275493A1 (en) 2002-10-08 2004-05-04 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
DE102004039326A1 (de) * 2004-08-12 2006-02-16 Abbott Gmbh & Co. Kg Neue medizinische Verwendungen und Verfahren
WO2006044617A1 (en) * 2004-10-15 2006-04-27 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
EP2937341B1 (en) 2004-12-30 2017-07-05 Janssen Pharmaceutica N.V. 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
US20090111778A1 (en) 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
AU2007217813A1 (en) * 2006-02-17 2007-08-30 The Scripps Research Institute Oxazole ketones as modulators of fatty acid amide hydrolase
CA2658887C (en) * 2006-07-28 2016-08-23 University Of Connecticut Fatty acid amide hydrolase inhibitors
JP2010502711A (ja) * 2006-09-08 2010-01-28 ザ スクリプス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼの置換オキサゾールケトンモジュレーター
WO2008147553A1 (en) * 2007-05-25 2008-12-04 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
JP2010533645A (ja) * 2007-05-31 2010-10-28 ザ スクリプス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼの三環系阻害剤
US8598202B2 (en) * 2008-02-19 2013-12-03 Janssen Pharmaceutica Nv Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
WO2009154785A2 (en) * 2008-06-19 2009-12-23 The Scripps Research Institute C4-substituted alpha-keto oxazoles
US8987312B2 (en) 2008-07-09 2015-03-24 The Scripps Research Institute Alpha-keto heterocycles as FAAH inhibitors
MX2011001313A (es) 2008-08-04 2011-03-04 Merck Sharp & Dohme Derivados de oxazol utiles como inhibidores de la amida hidrolasa de acidos grasos.
WO2010068452A1 (en) 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
AU2009330821B2 (en) * 2008-12-24 2015-06-11 Bial - Portela & Ca, S.A. Pharmaceutical compounds
AR076687A1 (es) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8901111B2 (en) 2009-06-05 2014-12-02 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
WO2011030798A1 (ja) 2009-09-09 2011-03-17 大日本住友製薬株式会社 ８－オキソジヒドロプリン誘導体
CN102647984B (zh) * 2009-10-02 2015-03-25 埃维克辛公司 抗炎症的2-羰基噻唑和2-羰基恶唑
US20120225097A1 (en) 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
RU2012136624A (ru) * 2010-01-28 2014-03-10 Мерк Шарп Энд Домэ Корп. Фармацевтические композиции для лечения боли и других показаний
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
WO2011133444A1 (en) 2010-04-21 2011-10-27 Merck Sharp & Dohme Corp. Substituted pyrimidines
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
ES2888231T3 (es) * 2010-09-20 2022-01-03 Sirna Therapeutics Inc Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
CN102964311B (zh) * 2011-09-01 2016-03-09 大丰海嘉诺药业有限公司 一种合成4-甲基-5-烷氧基噁唑的方法
CN104244948B (zh) * 2012-02-17 2016-11-16 爱普泰克集团有限公司 在炎症性疾病的治疗中使用的用于调节n-酰基乙醇胺的特异性酰胺酶的组合物和方法
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
EP3063144B1 (en) 2013-11-01 2021-09-08 Boehringer Ingelheim Animal Health USA Inc. Antiparasitic and pesticidal isoxazoline compounds
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
WO2016160168A1 (en) * 2015-02-20 2016-10-06 Cytec Industries Inc. Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
EP3095787A1 (en) * 2015-05-22 2016-11-23 Universiteit Leiden Pharmaceutically active compounds as dag-lipase inhibitors
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA19269A1 (fr) * 1980-09-16 1982-04-01 Lilly Co Eli Perfectionnement relatif a des derives de n-arylbenzamides .
US5821370A (en) * 1994-10-24 1998-10-13 Eli Lilly And Company Heterocyclic compounds and their preparation and use
TW200404789A (en) * 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
US6462054B1 (en) * 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
US20020103192A1 (en) * 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
AU2003275493A1 (en) 2002-10-08 2004-05-04 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase

Also Published As

Publication number Publication date
BR0314980A (pt) 2005-08-09
DE60327640D1 (ru) 2009-06-25
EP1549624A4 (en) 2006-09-20
AU2003275493A1 (en) 2004-05-04
JP4628789B2 (ja) 2011-02-09
EP1549624B1 (en) 2009-05-13
EA008767B1 (ru) 2007-08-31
EP1549624A2 (en) 2005-07-06
KR20050070041A (ko) 2005-07-05
ZA200501837B (en) 2006-06-28
ATE431342T1 (de) 2009-05-15
MXPA05003762A (es) 2005-07-22
CA2501575A1 (en) 2004-04-22
US7662971B2 (en) 2010-02-16
WO2004033652A2 (en) 2004-04-22
EP2093220A3 (en) 2009-11-11
JP2006502229A (ja) 2006-01-19
US20060111359A1 (en) 2006-05-25
WO2004033652A3 (en) 2004-09-16
ES2325686T3 (es) 2009-09-14
EP2093220A2 (en) 2009-08-26
CN1703407A (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
EA200500633A1 (ru) Ингибиторы гидролазы амидов жирных кислот
BRPI0508464A (pt) sulfonilpirróis
CO5251452A1 (es) Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar
SI2937341T1 (sl) Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj
DE60217363D1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen
EA200600509A1 (ru) Соединения пиримидотиофена
NO2015002I2 (no) Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
LU92555I2 (fr) Empagliflozine et ses sels, en particulier Empagliflozine (*) (*) l'ingrédient actif approuvé est l'Empagliflozine de formule (1S)-1,5anhydro-1-C-{4-chloro-3-¬(4-{¬(3S)-oxolan-3-yloxyl}phényl)méthylphényl}-D-glucitol
DE60143293D1 (de) Inhibitoren der 11-beta-hydroxy-steroid-dehydrogenase des typs 1
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
NO20040819L (no) Piezoelektrisk biologisk lydmonitor med kretskort.
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
ATE304003T1 (de) Thiadiazole und oxadiazole sowie ihre verwendung als phosphodiesterase-7 inhibitoren
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
ATE281181T1 (de) Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
HUP0100935A2 (hu) Amidvegyületet tartalmazó, szinergetikus hatású fungicid hatóanyag-keverék és alkalmazása
ATE289306T1 (de) N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen
RU2008108903A (ru) Пентациклический ингибитор киназы
NO20044250L (no) Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer
DE60332862D1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE60202669D1 (de) 6-phenylbenzonaphthyidine
NO20055399L (no) Hydroksamsyrer anvendelige ved behandling av hyper-proliferative forstyrrelser
DE50304858D1 (de) N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetemid-und entsprechende piperidinderivate als faktor xa inhibitoren zur behandlung von thromboembolischen erkrankungen
DE602004021854D1 (de) Pharmazeutisches präparat für die mundhöhle